Objective To discuss the diagonstic value of color Doppler ultrasonography and NAG-U , Uα1-MG ,Uβ2-MG in subclinical hepatorenal syndrome of liver cirrhosis. Methods The main renal artery diameter (D) , resistance index (RI) , as well as NAG-U , Uα1 -MG, Uβ2-MG were detected in the normal control subjects, 30 liver cirrhosis patients with compensation and 30 decompensation of live cirrhosis. Results The D and the RI of compensatory group were (0. 53 ±0. 04) cm and 0. 59 ±0. 06 respectivly, the D and the RI of the normal control subjects were (0. 56 ± 0.05) cm and 0. 57 ±0.08 respectivly, there were no differences between two groups (P>0.05). NAG-U, Uα1-MG, Uβ2-MG in compensatory group were (11.9 ±5. 6)U/L, (8. 15 ±2. 87) mg/L and (0. 31 ±0. 43) mg/L respectivly, and (6.4 ±3.2) U/L, (5.61 ±0. 35) mg/L, (0. 13 ±0. 1) mg/L in control subject, the differences in two groups were obvious (P <0. 01 ) . In decompensation group, D was (0. 39 ±0. 06) cm and RI was 0. 62 ±0. 04, as well as NAG-U (37.8 ±26.3) U/L,Uα1-MG (28. 07 ±20. 58) mg/L,Uβ2-MG (0. 71 ±0. 51) mg/L, compared with compensation group and nonmal control group, there were highly differences among three groups. Conclusion Doppler ultrasonography combined NAG-U, Uα1-MG, Uβ2-MG have an important role in tsubclimcal hepatorenal syndrome of liver cirrhosis.%目的 探讨彩色多普勒超声与尿N-乙酰-β-D氨基葡萄糖苷酶(NAG-U)、尿α1-微球蛋白(Uα1-MG)、尿β2-微球蛋白(Uβ2-MG)对肝硬化患者亚临床肝肾综合征(hepatorenal syndrome,HRS)的诊断价值.方法 选取体检正常者、代偿期肝硬化患者及失代偿期肝硬化患者各30例,应用多普勒超声检测主肾动脉内径(D)及叶间动脉阻力指数(RI),同时检测NAG-U、Uα1-MG、Uβ2-MG.结果 肝硬化代偿组D和RI分别为(0.53±0.04)cm、0.59±0.06,对照组分别为(0.56±0.05)cm、0.57±0.08,两组比较无统计学差异(P＞0.05);NAG-U为(11.9±5.6) U/L、Uα1-MG为(8.15±2.87)mg/L、Uβ2-MG为(0.31±0.43)mg/L,对照组分别为:(6.4±3.2)U/L、(5.61±0.35)mg/L、(0.13±0.1)mg/L,两组比较有显著性差异(P均<0.01);肝硬化失代偿组D和RI分别为(0.39±0.06)cm、0.62±0.04,NAG-U为(37.8±26.3)U/L、Uα1-MG为(28.07±20.58)mg/L、Uβ2-MG为(0.71±0.51)mg/L,与对照组和代偿组比较有明显差异(P＜0.01).结论 肝硬化病程进展中,多普勒超声能敏感、客观地反应肾脏血流动力学的改变,NAG-U、Uα1-MG、Uβ2-MG检测有助于早期发现肝硬化患者肾损害,二者结合对预测亚临床HRS的发生具有一定的意义.
展开▼
